The treatment of children affected by severe congenital neutropenia (SCN) with G-CSF strongly reduces the risk of sepsis by reversing neutropenia. However, SCN patients who respond to the treatment with the growth factor still have an elevated risk to succumb of sepsis. Because the disease is usually caused by heterozygous mutations of ELA2, a gene encoding for neutrophil elastase (NE), we have investigated in G-CSF-responder and non-responder patients affected by SCN the expression of polypeptides which constitute the anti-microbial machinery of these cells.
Introduction
Neutrophils are essential components of innate immune system because constitute the first line of defense against bacterial and fungal pathogens. An efficient response against these microorganisms needs that neutrophils carry a fully operational machinery including proteases, antimicrobial peptides and reactive oxygen 1, 2 . In contrast, a reduction of neutrophil blood counts or a defect in their anti-microbial apparatus exposes the host to threats from many pathogens as observed in chronic granulomatous disease and in other functional defects of phagocytes [3] [4] [5] [6] .
Severe congenital neutropenia (SCN) is an uncommon hematologic disorder characterized by reduction of absolute neutrophil counts (ANC; usually < 0.2 x10 9 cells/L), due to maturation arrest of neutrophil precursors in the bone marrow at the promyelocyte stage. If left untreated, the large majority of children affected by SCN dies in the first years of life from invasive infections 7, 8 .
However, the empiric use of the polypeptide granulocyte colony stimulating factor (G-CSF) for the treatment of SCN has drastically changed the clinical outcome of this condition by increasing absolute neutrophil count values and reducing the episodes of infection in the vast majority of patients [7] [8] [9] [10] . Nonetheless, SCN patients who are receiving G-CSF are at high risk of myelodisplastic syndrome (MDS) or acute myeloid leukemia (AML). In particular, a higher risk of MDS/AML is observed in SCN children who display a poor response to the treatment with G-CSF and/or receive large doses of the growth factor (above 8 µg/kg/day). In addition, even if the introduction of G-CSF in the treatment of SCN patients has dramatically improved survival and reduced morbidity from infections, infectious complications in treated patients are still observed at a rate of 0.9% per year 10, 11 .
In the last years the identification of the genetic basis of SCN has underlined the key role of neutrophil elastase (NE) in myelopoiesis and focused the attention of many researchers on the strict link between granule formation and neutrophil differentiation. Indeed, heterozygous mutations of the gene which encodes for neutrophil elastase (ELA2) constitute the molecular basis of this autosomal dominant inherited disease 12, 13 .
Molecular screening of ELA2 in patients with
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From congenital neutropenia has shown that patients with specific mutations (eg., G185R) are inclined to present a more severe clinical phenotype, requiring higher doses of G-CSF and, possibly, are at higher risk of developing MDS/AML 14, 15 . In this context, a primary question related to the use of this growth factor in this genetic disease is if G-CSF is capable to restore normal neutrophil functions besides correcting neutropenia.
In order to address this question, we have investigated in children affected by SCN receiving G-CSF whether the growth factor is able to correct neutropenia and/or to reconstitute the entire antimicrobial machinery of fully-matured neutrophils. Because granule protein synthesis and packaging of primary granules and thereafter of specific granules go along with promyelocytic differentiation up to mature neutrophils [16] [17] [18] , we analyzed expression of NE, myeloperoxidase (MPO), lactoferrin, cathepsin G, human neutrophil peptide (HNP), lysozime and NADPH oxidase components in cells isolated from SCN receiving G-CSF. We observed that ELA2 genotype strongly influenced the ability of G-CSF to correct neutropenia, but the expression and activity deficiency of many granuleassociated proteins was evident despite the correction of neutropenia by treatment with the growth factor.
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Methods
Approval for these studies was obtained from the Spedali Civili of Brescia institutional review board. Informed consent was provided according to the Declaration of Helsinki for the five with SCN, two with hidiopathic neutropenia subjects and for the healthy control subjects.
Patients and clinical details
Five SCN affected children (P1, P2, P3, P4, P5) and two with idiopathic neutropenia (C3 and C4)
were recruited from the haematological unit of Ospedale dei Bambini in Brescia. All these subjects were under treatment with G-CSF (5-40 µg/kg) at the time when the study was performed.
Diagnosis of all patients were made by experts on the basis of clinical and hematological data, valuating conventional criteria of persistent severe neutropenia, severe bacterial and fungal infection, and bone marrow maturation arrest at the myelocyte-promyelocyte stage. Patients P1 and P2 have been subjected to bone marrow transplantation while the other patients are currently receiving G-CSF treatment. However, patient P2 has recently lost the engraftment of donor's bone marrow and is currently receiving G-CSF. For each experiment performed, at least a healthy subject and/or an age matched child were included for comparison. The control group was used upon informed consent and consisted of healthy adult donors; two children with idiopathic neutropenia or age matched children who were admitted to the hospital for minor head trauma.
Mutational analysis
DNA was extracted from peripheral blood leukocytes using standard techniques. All five exons of ELA2 and at least 15 bases of flanking regions were amplified by PCR (primers and amplification conditions available upon request). PCR products were purified and bi-directionally sequenced as previously described using Big Dye Terminator Chemistry (Applied Biosystems) on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). For each new mutation found at least 50 healthy controls were screened using PCR amplification and direct sequencing. 
Neutrophils
Peripheral neutrophil cells were purified by Ficoll-Hypaque separation density-gradient centrifugation (Amersham Pharmacia Biotech, Uppsala, Sweden) from 5-10 ml of heparinized blood, followed by red cell lysis (NH4Cl 0.829%, EDTA 0.125mM, NaH2CO3 0.1%) and washing with PBS. Cell recovery varied from 1.5 x 10 6 cells (patients P1 and P2) up 4 x 10 6 cells (P3).
Neutrophil purity was assessed on the basis of May-Grünwald Giemsa stain, and of G-CSF receptor/CD15 expression at flow cytometry analysis, (neutrophils > 97%). Lactoferrin production by neutrophilic cells or lactoferrin plasma concentration was detected by sandwich ELISA system, using BIOXYTECH® Lactof-EIA™ assay provided by OXIS International Inc. (CA, USA), with a detection limit of 2 pg/ml. When indicated, neutrophils were stimulated with fMLP (10 nM), CXCL8 (10 ng/ml) or medium alone for 15 minutes. In the collected supernatants or plasma samples lactoferrin concentration was measured by ELISA and expressed as average ± SD of two distinct experiments.
Immunocytochemistry and immunofluorescence
Peripheral blood neutrophils were purified by Ficoll separation medium gradient centrifugation, followed by red cell lysis, and washing with PBS. Cells were counted and utilized for cytospin 
MPO activity assay
The EnzChek® Myeloperoxidase (MPO) Activity Assay Kit (E33856, Molecular Probes, Leiden, The Netherlands) was used for rapid and sensitive determination of MPO chlorination activity in neutrophil lysates. Fluorescence was measured with a fluorescence microplate reader using fluorescence excitation and emission at 485 and 530 nm, respectively. The background fluorescence measured for each zero-MPO control reaction was subtracted from each fluorescence measurement before plotting.
Phagocytosis assay
Neutrophils from patient 2 (P2) and from an healthy subject (CTR) were incubated for 40 min at 37°C with serum-opsonized zymosan (10 particles/cell) or serum-opsonized C. albicans (4 particles/cell), washed twice with PBS, transferred onto glass slides and stained with MayGrünwald Giemsa before examination under light microscopy.
Killing assay
Neutrophils were resuspended in HBSS/Ca 
Statistical analysis
Comparison of values between normal donors and patients were performed where indicated by ANOVA for unpaired data. For single comparison amongst groups, Bonferroni correction was applied. Differences were defined significant for p values lower than 0.05.
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Results
We have recently identified 5 SCN patients (ANC < 0.1 x10 9 cells/L) with various heterozygous mutations of ELA2 (Table 1) . In order to identify the biological correlates of the response to G-CSF in SCN patients, we evaluated the expression of neutrophil elastase and of other granule-associated protein in children with mutations of ELA2 during the treatment with the G-CSF (Table 1) . We found that patients P3 (P176fsX182) and P4 (N34-H41del) showed a satisfactory increase of neutrophil counts (3.6 and 1.9 x10 9 cells/L), while the remaining three (P2, G185R; P5 A98D) presented a blunted response to the treatment (0.8 x10 9 cells/L) or were not responsive (P1, G185R), even at high doses of G-CSF (up to 40 µg/kg).
Then we asked which was the effect of G-CSF on the expression of neutrophil elastase and myeloperoxidase, which are major components of primary granules and are synthesized at promyelocytic stage of maturation 20 . To this aim, we separated neutrophils from patients P1, P2
and P3, while they were receiving G-CSF and analyzed the expression of neutrophil elastase and of other granule-associated proteins. Immunofluorescence staining with anti-neutrophil elastase rabbit polyclonal antibody showed that expression of the protein was detectable only in a minority of cells derived from SCN patients, while it was abundantly present in cytoplasm of neutrophils from control subjects ( Figure 1A ). Neutrophil elastase is a monomeric polypeptide which is synthesized in endoplasmic reticulum as a 32 kDa, and subjected to glycosilation in Golgi apparatus.
Subsequent processing with removal of aminoterminal and carboxyterminal peptides takes place during its transport to primary granules where it stored as mature polypeptide of about 27-29 kDa 20, 21 . Analysis of neutrophil elastase expression by immunoblotting in SCN patients showed that the extent of protein expression was severely reduced in neutrophils of G-CSF-treated SCN patients, as compared to neutrophils of control subjects, in spite of G-CSF treatment ( Figure 1B) . Moreover, the relative amount of the different proteolytic polypeptides, of sizes ranging from the unprocessed 32 kDa form to the 29 kDa matured polypeptide, were dramatically altered, suggesting that normal neutrophil elastase processing is not restored in SCN patients during G-CSF treatment. Of note, analysis of NE expression in two patients with idiopathic neutropenia (C3 and C4), but normal ELA2, showed normal processing of the protein ( Figure 1B ). An analysis of NE expression in other 5 patients with severe neutropenia due to other causes in comparison to an additional SCN patient (P4) showed that the abnormal protein processing was not related to the treatment with G-CSF, but was strictly associated to ELA2 mutations (data not shown). Next, we evaluated ELA2 expression at the mRNA level in hematopoietic cells isolated from bone marrow of a SCN patient (P3). Analysis of ELA2 mRNA by Real Time PCR showed that the extent of expression in the cells derived from the patient was comparable to the control subject (data not shown). This is in accord to previous observations showing that ELA2 mutations lead to abnormal processing and intracellular targeting of the protein 15, 20 .
Next we investigated whether MPO, the other major constituent of primary granules is expressed and normally processed as tetrameric glycoprotein, consisting of two heavy (60 kDa) and two light chains (15 kDa), in neutrophils of SCN patients receiving G-CSF 22 . Immunocytochemical analysis of neutrophils obtained from SCN patients showed that MPO is absent or poorly expressed in cells, even while patients were receiving G-CSF therapy (Figure 2A ). In addition, western blot analysis showed that the electrophoretic mobility of the light chain was similar both in normal and in neutropenic patients, while the heavy chain had an abnormal size, suggesting an altered cleavage and/or glycosilation of MPO subunits ( Figure 2B ). Similarly to the 60 kDa heavy chain, a band of 40 kDa, most likely representing a degradation product of the heavy chain 23 , showed an altered electrophoretic mobility ( Figure 2B ). We then investigated whether abnormal MPO expressed by SCN patients was functional. To this purpose we analyzed the MPO-dependent chlorination activity in lysates of neutrophils isolated from patient 2 and we found that this activity was greatly reduced ( Figure 2C ).
We then evaluated the presence of other antimicrobial proteins in neutrophils and blood serum of G-CSF treated SCN patients. First we looked at lactoferrin, a constituent of specific granules, which
is also detectable in large amounts in blood circulation 24 . Specific granules are rapidly mobilized to cell surface in neutrophils activated by various stimuli, including chemoattractancts such as the formyl-MLP peptide (fMLP) and CXCL8, thereby leading to lactoferrin secretion 25 . Analysis of lactoferrin secretion in neutrophils from SCN patients showed that the antimicrobial protein was undetectable in supernatants obtained after stimulation with fMLP or IL-8, suggesting a reduced cellular content of the protein ( Figure 3A) . Indeed, blood lactoferrin concentration was severely reduced in all SCN patients ( Figure 3B ). In order to investigate intracellular expression of lactoferrin in neutrophils of SCN patients under treatment with G-CSF, we performed an immunoblot analysis of the protein. We found that lactoferrin was undetectable in neutrophil lysates from SCN patients bearing the G185R mutation (P1 and P2) while it was expressed at reduced levels in neutrophils of patient 3 (P3), as compared to levels detected in control subjects ( Figure   3C ).
We then analyzed the expression of other defensive proteins contained in primary and/or secondary granules of neutrophils by western blot analysis. We found that cathepsin G and mature HNP were undetectable, whereas HNP precursor was present in SCN neutrophil lysates (Figure 4 ). Moreover, lysozyme was normally expressed in neutrophils of the patients (Figure 4 ). Thereafter, we investigated the expression and function of NADPH oxidase, the multicomponent enzyme which plays a central role in host defense by catalyzing superoxide anion production. For its activity, it is required the assembly of the cytosolic subunits p47phox, p67phox, p40 phox and Rac with the membrane-associated heterodimer of gp91phox and p22phox 26, 27 . An immunoblot analysis showed that the NADPH oxidase cytosolic components p47phox, p67phox, and p40 phox were expressed at similar levels in control and SCN neutrophils, whereas the membrane-associated subunits gp91phox
and p22phox were reduced in neutrophils of patients ( Figure 5A ). In order to determine whether this alteration of NADPH oxidase subunits expression could affect the enzymatic activity of the complex, we evaluated superoxide anion release in neutrophils from SCN patients under treatment with G-CSF. We found that superoxide anion production was normal after SCN neutrophil
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Flow cytometry analysis of CXCR1 and fMLP receptor expression showed that the two G-protein coupled receptors were detectable in neutrophils of patient P3 as well as in cells of normal subjects (data not shown), suggesting that the impairment of fMLP-mediated oxidative burst is probably related to a defective signaling machinery.
Phagocytosis experiments showed that SCN neutrophils normally internalized both opsonized
Candida albicans and zymosan, and zymosan ingestion induced superoxide anion production ( Figure 5C ), suggesting that the mechanisms involved in pathogens uptake and in phagocytosisdependent oxygen radical production are conserved in these cells.
We finally investigated whether the reduction and/or abnormality of defensive proteins observed in SCN neutrophils results in a decreased anti-microbial activity. To this aim we analyzed the ability of neutrophils from one SNC patient to kill C. albicans and E. coli. We found that these cells were unable to inhibit Candida growth, whereas their capacity bactericidal activity against E. coli was significantly reduced (p< 0.05, Figure 5D ), suggesting a defect of neutrophils from SCN patients to control infections from these microorganisms. 35, 36 . In contrast to these findings, we were unable to detect differences of ELA2 mRNA levels in total hematopietic cells isolated from bone marrow of P3; but, the effect of ELA2 mutations on mRNA expression might not be detectable in total hematopoietic cells from bone marrow but only in selected myeloid precursors.
Investigation on NE, MPO and lactoferrin expression in neutrophils of the two SCN patients with the G185R mutation has shown that the defect of the abnormal processing of these polypetides is more striking in these patients suggesting that the corresponding mutant has a profound effect on the early stages of neutrophil differentiation. It is interesting that transfection studies of the G185R mutant into RBL cell line have shown that this protein cannot be revealed by immunofluorescence while it is still detectable by immunoblotting 21 . Moreover, we found that children with a refractory response to G-CSF and the G185R genotype expressed an extremely low amount of lactoferrin, while the antimicrobial protein was still detected in cell extracts of patients with other ELA2 mutations or with other causes of neutropenia under treatment with G-CSF 36, 37 suggesting that an early death of promyelocytes during their differentiation prevented the formation of specific granules 15, 38 .
This succession of events is not fully restored by treatment with G-CSF, although we observed a great degree of variability in the severity of the maturation defect among children with different
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From types of ELA2 mutations. Therefore, the incomplete maturation of neutrophils in SCN may explain why a significant number of cases of patients die from sepsis (8 % of cumulative incidence over 10 years) even if they had shown a satisfactory response to the treatment with G-CSF 11 . In fact, while the observed risk to die of sepsis was higher in the patients less responsive to the growth factor (14%) as compared to children with good response (11%), the use of G-CSF was not sufficient to prevent lethal infections in these children. The increased susceptibility to infections might be related to the abnormal expression in neutrophils of SCN patients of antimicrobial polypetides, such as NE, lactoferrin, MPO, cathepsin G and HNP, in spite of the treatment of the patients with G-CSF. It is conceivable that the decreased expression of these peptides by neutrophils of SCN patients could lead to an impairment of their antimicrobial functions. In fact, we report that these cells were unable to kill C. albicans and showed a decreased killing activity against E. coli. Therefore, it is likely that the antimicrobial activities which are dependent on MPO, lactoferrin, cathepsin G, HNP and, other unknown abnormal proteins, are not correctly functioning in neutrophils of SCN patients; whereas the defense mechanisms which require polypeptides such as lysozyme which are correctly expressed in cells of SNC patients, are still effective against some microorganisms. Notably, we found that phagocytosis is apparently normal in SCN neutrophils, suggesting that the reduced killing ability of these cells does not rely on defects of microbial internalization. Moreover, although the expression of membrane-associated NADPH oxidase subunits is decreased, oxygen radicals production in response to PMA and zymosan particles is conserved in SCN neutrophils, whereas it is defective upon fMLP stimulation. Therefore, activation mechanisms of oxygendependent killing machinery appear to be only partially conserved in SCN neutrophils, in spite of the treatment of patients with G-CSF.
Clearly, further studies are needed to determine whether the defect of granule formation can be generalized to all SCN patients treated with G-CSF, but these new results and previous evidence that G-CSF therapy accelerates leukemogenesis in SCN call into question the overall efficacy of treatment with G-CSF and raise the issue of whether it should even be used for the treatment of this 
Acknowledgments
We are grateful to Silvia Costa for help with Western blot experiments, Tiziana Musso for critical were subjected to Western Blot analysis with anti-gp91phox, p47phox, p67phox, p40phox, or p22phox specific antibodies. The gp91phox appears as a broad smear because it is highly glycosilated. β-actin was used to compare protein levels. (B) Neutrophils (2x10 5 ) from patient 1 (P1) and 3 (P3) and from an healthy subject (CTR) were stimulated with 100 nM fMLP or 20 ng/ml PMA for 60 min. When required cells were pre-incubated with 50 ng/ml G-CSF or GM-CSF for 30 Statistical analysis demonstrates that anti-microbial activities of neutrophils against C. albicans and E. coli are reduced in SCN patient as compared to an healthy subject (p <0.05)
